Perrigo Company PLC (PRGO) closed at $15.85 on November 6, 2026, up 0.9% from the previous close, on volume of 2,079,579 shares (30-day average 2,449,680).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Ratio Call Spread 34 by 29 | 20-Nov-2615[34x] : 17.5[29x] C | 819 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Canaccord Genuity Reaffirms Their Buy Rating on Perrigo Company (PRGO)
TipRanks (Thu, 5-Nov 7:29 AM ET)
Perrigo Non-GAAP EPS of $0.60 beats by $0.07, revenue of $989M misses by $6.9M
Seeking Alpha News (Wed, 4-Nov 6:34 AM ET)
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
PRNewswire (Wed, 4-Nov 6:30 AM ET)
Perrigo Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 11:08 AM ET)
Perrigo Announces Quarterly Dividend
PRNewswire (Thu, 29-Oct 12:31 PM ET)
Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade
PRNewswire (Thu, 29-Oct 9:01 AM ET)
Perrigo Sets November 4 Date for Q3 2026 Results and 8:30 a.m. ET Conference Call
Market Chameleon (Wed, 21-Oct 7:51 AM ET)
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
PRNewswire (Wed, 21-Oct 8:31 AM ET)
Perrigo to Attend the Barclays Global Consumer Conference
PRNewswire (Thu, 27-Aug 8:31 AM ET)
Perrigo Targets Streamlined, Focused Growth Despite Revenue Dip and Margin Pressure in Q2 2026
Market Chameleon (Wed, 5-Aug 7:45 AM ET)
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Perrigo Company PLC trades on the NYSE stock market under the symbol PRGO.
As of November 6, 2026, PRGO stock price climbed to $15.85 with 2,079,579 million shares trading.
PRGO has a beta of 2.38, meaning it tends to be more sensitive to market movements. PRGO has a correlation of 0.19 to the broad based SPY ETF.
PRGO has a market cap of $2.20 billion. This is considered a Mid Cap stock.
Last quarter Perrigo Company PLC reported $989 million in Revenue and $.60 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.06.
In the last 3 years, PRGO traded as high as $34.60 and as low as $9.23.
The top ETF exchange traded funds that PRGO belongs to (by Net Assets): IJR, AVUV, VTI, IWM, VB.
PRGO has outperformed the market in the last year with a price return of +13.9% while the SPY ETF gained +10.8%. PRGO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.7% and -0.7%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
PRGO support price is $15.23 and resistance is $16.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRGO shares will trade within this expected range on the day.
